Citations

Clear

4207 citation(s) found for "Chen, Yu".

Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2
Harding, James J. , Oh, Do‐Youn , Macarulla, Teresa , Goyal, Lipika , Varkaris, Andreas , Palmieri, Lola‐Jade , Ikeda, Masafumi , Kondo, Shunsuke , Bai, Li‐Yuan , Ueno, Makoto , Papadopoulos, Kyriakos P. , Shroff, Rachna T. , Kizilbash, Sani H. , Liao, Chih‐Yi , Azad, Nilofer S. , Jaeckle, Kurt A. , Bender, Mark H. , Varughese, Sunoj Chacko , Sachdeva, Deepa , Radtke, David B. , Gueorguieva, Ivelina , Chen, Hsiao-Rong , Liu, Hui , Xu, Xiangyuan , Macarulla, Teresa , Chen, Li-Tzong , Papadopoulos, Kyriakos P , Shroff, Rachna T , Kizilbash, Sani H , Hollebecque, Antoine , Adeva, Jorge , Cosman, Rasha , Yokota, Tomoya , Park, Joon Oh , Turk, Anita , Liao, Chih-Yi , Satoh, Taroh , Borad, Mitesh J , El-Khouiery, Anthony B , Azad, Nilofer , Jaeckle, Kurt A , Loong, Herbert H , Yong, Wei-Peng , Bender, Mark H , Varughese, Sunoj Chacko , Sachdeva, Deepa , Radtke, David B , Gueorguieva, Ivelina , Szpurka, Anna M , Chen, Hsiao-Rong , Liu, Hui , Xu, Xiaojian , Rodon, Jordi , Ikeda, Masafumi , Goyal, Lipika , Harding, James J , Chen, Li‐Tzong , Adeva, Jorge , Yokota, Tomoya , Borad, Mitesh J. , El-Khoueiry, Anthony B. , Loong, Herbert H. , Yong, Wei Peng

Mayo Clinic

Clinical Cancer Research | September 30, 2025 | Volume: 31 | Issue: 23 | Pages: 4920-4932

10.1158/1078-0432.ccr-25-0174 | PMID 41026608 Get It

Abstract Purpose: Isocitrate dehydrogenase (IDH) 1/2–isoform inhibitors have clinical efficacy in IDH1/IDH2-mutated neoplasms. However, primary resistance and secondary resistance limit their therapeutic potential. LY3410738, an oral, brain-penetrant, dual IDH1/IDH2-mutated isoform-selective inhibitor, was designed to overcome resistance. Patients and Methods: This global, multicenter, open-label, phase I study of patients with IDH-mutant solid tumors evaluated LY3410738 as monotherapy (dose escalation) for advanced solid tumors in combination with cisplatin–gemcitabine (CISGEM) for newly diagnosed cholangiocarcinoma or with durvalumab for relapsed/refractory cholangiocarcinoma (dose expansion; NCT04521686). Primary objectives were the maximum tolerated dose, recommended phase II dose, and preliminary antitumor activity. Safety, pharmacokinetics, inhibition of D-2-hydroxyglutarate, and ctDNA were assessed. Results: Overall, 119 patients received LY3410738 alone (N = 94) or in combination with CISGEM (N = 19) or durvalumab (N = 6). No dose-limiting toxicities were observed; the maximum tolerated dose was not determined. Common adverse events included nausea, vomiting, and decreased appetite. Overall response rates of 5.2% and 11.1% and disease control rates of 56.9% and 63.0% were observed for patients with relapsed/refractory IDH1- or IDH2-mutant cholangiocarcinoma or IDH1-mutant glioma, respectively. D-2-hydroxyglutarate normalization was rapid and durable. In dose-expansion cohorts, combination treatments were tolerable, with one dose-limiting toxicity in the durvalumab cohort. LY3410738 plus CISGEM demonstrated a response rate of 42.1%, a median duration of response of 8.1 months, and a median progression-free survival of 10.2 months for patients with newly diagnosed IDH-mutant cholangiocarcinoma. Conclusions: LY3410738 demonstrated largely cytostatic antitumor activity in IDH1- or IDH2-mutated cholangiocarcinoma and IDH1-mutated gliomas. LY3410738 plus CISGEM exhibited favorable antitumor activity in patients with treatment-naïve IDH-mutated cholangiocarcinoma, warranting further exploration as a treatment strategy.
A Multicenter Study of an Investigational Extended Wear Insulin Infusion Set in Adults with Type 1 Diabetes
Lal, Rayhan A. , Lum, John W. , Reed, Zachariah W., Kruger, Davida , Reed, John Chip, Weinstock, Ruth S. , Carlson, Anders L. , Kudva, Yogish C. , Liljenquist, David R., Levister, Camilla, Broyles, Frances E. , Pinsker, Jordan E. , Romey, Matt, Lehman, Avi, Muchmore, Douglas B. , Kollman, Craig, Group, for the CB1 Study, Hirsch, Irl B , Pinsker, Jordan E , Beck, Roy W , Lal, Rayhan A , Lal, Rayhan A. , Reed, John H. Chip, Aleppo, Grazia , Chen, Jean, Ahn, David , Hirsch, Irl B. , Putman, Melissa S. , Pinsker, Jordan E. , Beck, Roy W. , Group, for the CB1 Study

Mayo Clinic

Diabetes Technology & Therapeutics | September 30, 2025 | Volume: 28 | Issue: 1 | Pages: 1-9

10.1177/15209156251364548 | PMID 40780817 Get It

Objective: To evaluate the function and safety of the SteadiSet™ infusion set over a continuous 7-day wear period in adults with type 1 diabetes. Research Design and Methods: Participants used a SteadiSet infusion set with a t:slim X2™ insulin pump with Control-IQ™ technology, and either insulin aspart or insulin lispro, for a target of 7 days for 12 consecutive wear periods. Each set removed before 7 days was adjudicated by an independent committee to assess the cause of early removal and to determine whether criteria for primary or key secondary endpoints were met. Results: There were 260 participants who inserted 3028 infusion sets. For the primary endpoint, the Kaplan–Meier 7-day survival estimate was 95% (95% CI 94% to 96%). For the key secondary endpoint, which expanded the reasons for a failed infusion set, the Kaplan–Meier 7-day survival estimate was 84% (95% CI 82% to 86%). For both endpoints, the P value was <0.001 compared with a prespecified survival rate of 75%. Time-in-range 70–180 mg/dL (TIR) increased through day 3 of set wear and then decreased through day 7, with the average TIR being 70.6% over the entire wear period across all infusion sets, including those that failed. An increase in total daily insulin was observed from day 4 through day 7. Conclusions: The 7-day survival of the SteadiSet infusion set was very high for the primary endpoint and at an acceptable level with respect to early removal for any reason related to the device.
Diagnosis, Prognosis, and Drug Target Discovery for Chronic Widespread Pain: A Large Proteogenomic Study
Meng, Ruogu , Liu, Duanke, Guo, Yuchen, Wang, Yunhe, Gao, Yaqing , Huang, Zhe , Zhu, Liang , Zeng, Chao , Ma, Jun , Irani, Anushka, Lei, Guanghua, Irani, Anushka , Chen, Li , Xie, Junqing , Irani, Anushka , Kelleher, Eoin , Guo, Yuchen, Wang, Yunhe, Yuan, Shuai , Dong, Yanhui, Lei, Guanghua, Prieto‐Alhambra, Daniel

Mayo Clinic

Advanced Science | September 30, 2025 | Volume: 12 | Issue: 47 | Pages: No page available

10.1002/advs.202507691 | PMID 41025730 Get It

Abstract Chronic widespread pain (CWP) remains challenging due to its heterogeneous causes and complex mechanisms. A total of 2920 plasma proteins are analyzed from 29,254 UK Biobank participants. A total of 256 proteins are identified as cross‐sectionally correlated with CWP. A simple (top 10 proteins) and comprehensive (all significant proteins) proteomic‐based score (ProtS) is created for CWP diagnosis, both outperforming and improving the existing clinical score (area under the curve, AUC: 0.801, 0.723, and 0.791 alone, and 0.856 and 0.880 in combination). In addition, the protein score predicted 13‐years risk of pain‐related traits over the body, including pain onset, progression, and intensity; Moreover, it has stronger associations with nociplastic pain and fibromyalgia compared to nociceptive and neuropathic pain, implying a unique protein signature of different pain mechanisms. Finally, among 434 candidate proteins prioritized in the observational analysis, 18 are corroborated with causal relevance by Mendelian randomization, and importantly, four (CA14, DPEP1, LGALS3, and TNF) showed potential as novel drug targets repurposed for treating CWP.
Multiomics combined with machine learning defines unique molecular subtypes of cholangiocarcinoma and identifies TNK1 as a therapeutic target
Mun, Dong‐Gi , Jessen, Erik , Carlson, Danielle M. , Watkins, Ryan , Gregory, Lindsey A., McCabe, Chantal E. , Golkowski, Martin , Baker, Marshall S., Conboy, Caitlin B. , Ozmert, Enis H., Kandasamy, Richard K. , Roberts, Lewis R. , Andersen, Joshua L. , Smoot, Rory L. , Tomlinson, Jennifer L. , Abdelrahman, Amro , Gregory, Lindsey, Conboy, Caitlin, Larson, Ellen L. , Roberts, Lewis, Pandey, Akhilesh , Jessen, Erik , Roberts, Lewis R , Smoot, Rory L , Kandasamy, Richard K , Conboy, Caitlin B , Mun, Dong-Gi , Carlson, Danielle Marie , Budhraja, Rohit , Alva‐Ruiz, Roberto , Abdelrahman, Amro M. , Wang, Chen , Graham, Rondell P. , Woods, Kathryn, Gores, Gregory J. , Ilyas, Sumera I. , Sample, Jack W. , Borad, Mitesh J. , Pandey, Akhilesh

Mayo Clinic

Hepatology | September 29, 2025 | Volume: 84 | Issue: 2 | Pages: 396-410

10.1097/hep.0000000000001535 | PMID 41020779 Get It

Background and Aims: Cholangiocarcinoma (CCA) is one of the most lethal cancers, characterized by molecular heterogeneity and treatment resistance. To uncover new biological signals and therapeutic opportunities, we employed multiomic characterization combined with machine learning. Approach and Results: We profiled all anatomical CCA subtypes using whole exome sequencing, mRNA sequencing, and proteome/phosphoproteome analysis. Integrative dimensional reduction revealed RNA, protein, and phosphoprotein features driving tumor heterogeneity, enabling clustering. Machine learning algorithms identified molecular features for each cluster and mapped external datasets and patient-derived xenograft (PDX) models onto these clusters. Kinase enrichment analysis highlighted targetable kinases active in each cluster. In vivo validation was performed in cluster-specific PDX models using the selective TNK1 inhibitor, TP-5801. We identified 3 molecular clusters with distinct pathway characterization: immunomodulatory (cluster 1), metabolic (cluster 2), and gene regulation/cellular fate (cluster 3). Cluster assignment was independent of anatomic subtype but correlated with overall survival following curative-intent resection. We also identified multiomic features and pathways linked to overall survival and lymph node metastases, crucial for patient treatment selection. Kinase enrichment analysis pinpointed TNK1 as a highly active kinase in the metabolic cluster. Treatment with TP-5801 significantly reduced tumor growth in a metabolic PDX model, but not in models representing the other clusters. Combining internal data with publicly available datasets, we identified the immunomodulatory cluster as most responsive to gemcitabine/cisplatin therapy, confirmed in vivo using cluster-specific PDX models. Conclusions: Integrated multiomic characterization provides translational insights by defining unique molecular subtypes associated both with therapeutic response and overall clinical outcomes. This approach identified TNK1 as a previously unrecognized therapeutic target in a defined subset of CCA tumors.
The Relationship Between Non-Invasive Tests and Digital Pathology for Quantifying Liver Fibrosis in MASLD
Wei, Xiaodie , Qiu, Lixia , Wang, Xinxin , Shao, Chen , Zhao, Jing , Chen, Jun , Yin, Meng , Ehman, Richard L. , Zhang, Jing , Yin, Meng , Ehman, Richard , Yang, Qiang

Mayo Clinic

Diagnostics | September 29, 2025 | Volume: 15 | Issue: 19 | Pages: 2475

10.3390/diagnostics15192475 | PMID 41095694 Get It

Background: It is crucial to evaluate liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD). Digital pathology, an automated method for quantitative fibrosis measurement, provides valuable support to pathologists by providing refined continuous metrics and addressing inter-observer variability. Although non-invasive tests (NITs) have been validated as consistent with manual pathology, the relationship between digital pathology and NITs remains unexplored. Methods: This study included 99 biopsy-proven MASLD patients. Quantitative-fibrosis (Q-Fibrosis) used second-harmonic generation/two-photon excitation fluorescence microscopy (SHG/TPEF) to quantify fibrosis parameters (q-FPs). Correlations between eight NITs and q-FPs were analyzed. Results: Using manual pathology as standard, Q-Fibrosis exhibited excellent diagnostic performance in fibrosis stages assessment with area under the receiver operating characteristic curves (AUCs) ranging from 0.924 to 0.967. In addition, magnetic resonance elastography (MRE) achieved the highest diagnostic accuracy (AUC: 0.781–0.977) among the eight NITs. Furthermore, MRE-assessed liver stiffness measurement (MRE-LSM) showed the strongest correlation with q-FPs, particularly adjusted by string length, string width, and the number of short and thick strings within the portal region. Conclusions: Both MRE and digital pathology demonstrated excellent diagnostic accuracy. MRE-LSM was primarily determined by collagen extent, location and pattern, which provide a new perspective for understanding the relationship between the change in MRE and histological fibrosis reverse.
Large language models for bioinformatics
Ruan, Wei, Lyu, Yanjun , Zhang, Jing , Cai, Jiazhang , Lu, Yao , Wang, Tao , Liu, Yufang , Fang, Luyang , Liu, Ziyu , Liu, Zhengliang , Li, Yiwei , Wu, Zihao , Chen, Junhao , Jiang, Hanqi, Yang, Zhenyuan, Liang, Shizhe, Zhang, Wei , Ma, Terry, Dou, Yuan , Zhang, Jianli , Gong, Xinyu , Gan, Qi , Zou, Yusong , Chen, Z. J. , Qian, Yuanxin, Yu, Shuo , Song, Kenan, Sikora, Andrea, Li, Xiang , Wang, Yingfeng , Zhong, Wenxuan, Liu, Rongjie , Huang, Chao , Shen, Ye , Yan, Yajun , Liu, Tianming, Huang, Chao , Song, Kenan , Wang, Peilong, Chen, Jingyuan, Song, Kenan , Ruan, Wei, Shu, Peng , Yang, Ge , Gao, Shang , Wang, Yue , Wang, Peilong , Zhao, Lin , Jiang, Hanqi , Pan, Yi Feng , Chen, Jingyuan , Dou, Yuan, Chen, Z. J. , Qian, Yuanxin, Jin, Lu , Wang, Xianqiao , Sikora, Andrea , Li, Gang , Li, Quanzheng , Zhang, Lu, Abate, Yohannes , He, Lifang , Zhong, Wenxuan, Liu, Wei , Ma, Ping , Zhu, Hongtu , Zhu, Dajiang

Mayo Clinic

Quantitative Biology | September 29, 2025 | Volume: 14 | Issue: 1 | Pages: No page available

10.1002/qub2.70014 | PMID 41676319 Get It

Abstract With the rapid advancements in large language model technology and the emergence of bioinformatics‐specific language models (BioLMs), there is a growing need for a comprehensive analysis of the current landscape, computational characteristics, and diverse applications. This survey aims to address this need by providing a thorough review of BioLMs, focusing on their evolution, classification, and distinguishing features, alongside a detailed examination of training methodologies, datasets, and evaluation frameworks. We explore the wide‐ranging applications of BioLMs in critical areas such as disease diagnosis, drug discovery, and vaccine development, highlighting their impact and transformative potential in bioinformatics. We identify key challenges and limitations inherent in BioLMs, including data privacy and security concerns, interpretability issues, biases in training data and model outputs, and domain adaptation complexities. Finally, we highlight emerging trends and future directions, offering valuable insights to guide researchers and clinicians toward advancing BioLMs for increasingly sophisticated biological and clinical applications.
Diminished preparatory physiological responses in people with dementia: associations with caregiver health and relationship quality
Chen, Kuan‐Hua , Scheffer, Julian A. , Chen, Enna , Yee, Claire , Wells, Jenna L. , Lwi, Sandy J. , Grimm, Kevin J. , Merrilees, Jennifer , Yee, Claire , Grimm, Kevin , Levenson, Robert W , Levenson, Robert W.

Mayo Clinic

The Journals of Gerontology, Series B: Psychological Sciences and Social Sciences | September 27, 2025 | Volume: 80 | Issue: 12 | Pages: No page available

10.1093/geronb/gbaf187 | PMID 41021459 Get It

Abstract Objectives Emotional impairments in people with dementia can be taxing for family caregivers. However, caregivers differ in their resilience to these challenges. We previously found that, compared to healthy controls and people with Alzheimer’s disease, people with frontotemporal lobar degeneration (FTLD) have smaller physiological responses when anticipating upcoming emotional stimuli. This impairment may leave these people with FTLD unprepared for upcoming emotional stimuli because they cannot mount responses needed for appropriate behaviors, which may create stress and difficulties for caregivers. We examined (a) whether smaller preparatory physiological responses in people with dementia are associated with lower emotional well-being and physical functioning in caregivers; and (b) whether these associations are moderated by the dyads’ relationship quality. Methods A total of 158 individuals with FTLD or Alzheimer’s disease and their family caregivers participated. Preparatory physiological responses in people with dementia were quantified as decreases in cardiac interbeat intervals from baseline to an instruction period, during which they were told they would be watching an upcoming emotional film. Caregivers self-reported their emotional well-being, physical functioning, and relationship quality with the people with dementia. Results Smaller preparatory physiological responses in people with dementia were associated with lower emotional well-being (but not physical functioning) in caregivers. This association was moderated by relationship quality (i.e., weakened for caregivers in higher-quality relationships). Discussion Findings advance understanding of risk and resilience factors for negative caregiver outcomes. Positive interpersonal processes in high-quality relationships (e.g., positive appraisal of aberrant behaviors) may buffer caregivers from the impact of emotional impairments in people with dementia.
Linkage disequilibrium score regression identifies genetic correlations between hepatocellular carcinoma and clinically relevant traits
Shaw, Vikram R. , Byun, Jinyoung , Thrift, Aaron P. , Zhu, Catherine , Li, Donghui , Kelley, Robin Kate , Bracci, Paige M. , Bucur, Roxana , Knox, J. David, Jalal, Prasun K. , Ghobrial, R. Mark , Nguyen, Mindie H. , Parikh, Neehar D. , Wu, Hui‐Chen , El‐Serag, Hashem, Chang, Ping , Chun, Yun Shin , Gu, Jian , Huff, Chad D. , Rashid, Asif, Hwang, Lu‐Yu, Khaderi, Saira, Roberts, Lewis R. , Hassan, Manal M. , Shaw, Vikram R , Byun, Jinyoung , Thrift, Aaron P , Permuth, Jennifer B , Yuan, Jian-Min , Nguyen, Mindie H , Kim, Richard , Gu, Jian , Kaseb, Ahmed O , McGlynn, Katherine A , Roberts, Lewis R , Parikh, Neehar D , Jalal, Prasun K , Han, Younghun , Hatia, Rikita , Cleary, Sean P. , Lok, Anna S. , Permuth, Jennifer B. , Knox, Jennifer, Singal, Amit G. , Kono, Yuko , Shah, Dimpy P. , Kim, Richard D. , El‐Serag, Hashem B. , Rashid, Asif , Klein, Alison P. , McGlynn, Katherine A. , Amos, Christopher I.

Mayo Clinic

International Journal of Cancer | September 27, 2025 | Volume: 158 | Issue: 5 | Pages: 1193-1203

10.1002/ijc.70136 | PMID 41013983 Get It

Abstract Hepatocellular carcinoma (HCC) mortality is increasing globally, partly due to the growing prevalence of nonviral liver diseases. Genome‐wide association studies (GWAS) have identified genetic variants associated with HCC development. Leveraging GWAS summary statistics and linkage disequilibrium score regression (LDSR), we investigated disease co‐development with hepatitis C virus‐negative (HCV‐negative) HCC to provide unique insights into HCC etiology and prioritize relationships for further causal inquiry. We utilized the LDSR statistical framework to estimate the genetic correlation and heritability between HCV‐negative HCC with 901 epidemiologic, behavioral, and clinical traits from the United Kingdom Biobank (UKBB). First, we set the threshold for observed scale heritability of each trait at 0.02 to ensure reliable inferences with adequate study power. Next, we observed significant positive genetic correlations between HCV‐negative HCC and blood‐based biomarkers of liver injury (ALT, GGT) and allostatic load (including glycated hemoglobin, blood pressure, and total albumin). We also identified a positive genetic correlation between HCV‐negative HCC and diseases associated with metabolic dysfunction‐associated steatotic liver disease (MASLD), including diabetes, hypertension, chronic ischemic heart disease, and others. Taken together, our results help to identify polygenic and pleiotropic signals related to different phenotypic traits associated with HCC and support further exploration of the predictive power of blood‐based biomarkers identified in this study for inferring HCC development among HCV‐negative individuals.
Advancing delirium detection through the Open Health Natural Language Processing Consortium and the Evolve to Next-Gen Accrual to Clinical Trials Network
Fu, Sunyang , Kwak, Min Ji , Ahn, Jaerong, Yue, Zhiyi , Ranganath, Shreyas, Applegate, Joseph R., Wang, Liwei , Li, Chenyu , Toth, Kelly M, Girard, Timothy D., Osborne, John D. , Kennedy, Richard , Garduno-Rapp, Nelly-Estefanie, Reeder, Phillip , Murphy, Thomas J. , Heling, Jia, Sohn, Sunghwan , Visweswaran, Shyam, Wang, Yanshan , Girard, Timothy D. , Li, Chenyu , Rousseau, Justin F , Yan, Chao , Murphy, Tyler J , Park, Chan Mi , Bernstam, Elmer V , Visweswaran, Shyam , Liu, Hongfang , Girard, Timothy D , Fu, Sunyang , Kennedy, Richard E , Osborne, John D , Wang, Yanshan , Ahn, Jaerong, Applegate, Joseph R, Wen, Andrew , Morris, Michele M. , Toth, Kelly M, Rousseau, Justin F. , Chen, You , Patel, Mayur Bipin , Malin, Bradley , Jia, Heling, Pagali, Sandeep R. , Palmer, Allyson K. , Sauver, Jennifer L. St. , Liu, Hongfang

Mayo Clinic

The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences | September 26, 2025 | Volume: 80 | Issue: 12 | Pages: No page available

10.1093/gerona/glaf207 | PMID 41017643 Get It

Abstract Background Delirium is often underdiagnosed in clinical practice and is not routinely coded for billing. While manual chart review can identify delirium, it is labor-intensive and impractical for large-scale studies. Natural language processing (NLP) can analyze unstructured text in electronic health records (EHRs) to extract meaningful clinical information. Methods To support national integration of NLP for EHR-based delirium identification across different institutions, we launched the Delirium Interest Group within the national Evolve to Next-Gen Accrual to Clinical Trials (ENACT) NLP Working Group. This paper outlines our initial efforts to standardize, evaluate, and translate an NLP-based delirium detection model into the i2b2/ENACT platform. Results Multisite contextual inquiry identified several key challenges, including variations in local screening practices (eg, tools used, documentation frequency, and quality control), the need for harmonized definitions in the context of EHRs, and the complexity of modeling temporal logic. Multisite NLP evaluation revealed variable performance degradation driven by differences in delirium screening practices, clinical documentation patterns and semantics, and note syntactic structures. Conclusion Our work represents an important first step toward enabling scalable and standardized NLP-based delirium detection across institutions. By engaging diverse institutions through the ENACT NLP Working Group, we identified shared challenges and site-specific variations that impact model implementation and performance. Our collaborative approach enabled the development of a more robust framework for delirium identification across heterogeneous EHR systems. Future efforts will build on this foundation to enhance the validity, usability, and translational impact of delirium detection.
Intracranial Occlusion in Cryptogenic Stroke Is Not Predictive of Recurrent Ischemic Stroke: A Propensity‐Score Matched Analysis of the Cardiac Abnormalities in Stroke Prevention and Risk of Recurrence Study
Brorson, James R. , Badillo‐Goicoechea, Elena , Penckofer, Mary , Eklund, Kelsey , Stretz, Christoph , Lineback, Christina M. , Khasiyev, Farid , Kerrigan, Deborah , Lewis, Skylar, Ali, Hamid , Melkumova, Emiliya , Dumitrascu, Oana M. , Parikh, Parth , Doolittle, Charles, Yahnke, Ian, Sathya, Anvitha , Brown, Samantha , Kang, Jieun, Bowman, Anna, Shahrivari, Mahan, Sehgal, S , Alvi, Muhammad , Krishnaiah, Balaji , Kam, Wayneho , Kothari, Sachin , Qdais, Ahmad Abu, Quintela, Gustavo Antezana, Sharma, Richa, Thottempudi, Neeharika, Nedelcu, Simona , Herpich, Franziska , Glover, Patrick , Chahien, Dalia, Liebeskind, David S. , Linares, Guillermo , Daniel, Jean‐Philippe, Kasab, Sami Al , Singh, Eesha , D’Souza, Maria , Gaudio, Elizabeth, Kala, Narendra , Sarkar, Monica , Coevering, Russell J. Van , Thon, Jesse , Thompson, Sean, Lineback, Christina , Brorson, James R , Penckofer, Mary , Eklund, Kelsey , Stretz, Christoph , Lineback, Christina M , Khasiyev, Farid , Kerrigan, Deborah , Ali, Hamid , Aboul-Nour, Hassan , de Havenon, Adam H , Culbertson, Collin J , Melkumova, Emiliya , Jillella, Dinesh V , Dumitrascu, Oana M , Parikh, Parth , Sathya, Anvitha , Brown, Samantha J , Elangovan, Cheran , Sehgal, Siddharth , Sloane, Kelly L , Krishnaiah, Balaji , Kam, Wayneho , Kothari, Sachin , Farooqui, Mudassir , Nahab, Fadi B , Sharma, Richa , Nedelcu, Simona , Herpich, Franziska , Liebeskind, David S. , Linares, Guillermo , Al Kasab, Sami , Aziz, Yasmin , Yaghi, Shadi , Goldstein, Eric D , Van Coevering, Russell J , Thon, Jesse , Stamm, Brian , Siegler, James E , Lineback, Christina M , Daniel, Jean-Philippe Auguste , Smith, Matthew M. , Nour, Hassan Aboul , Havenon, Adam de , Jillella, Dinesh , Doolittle, Charles, Elangovan, Cheran , Sharma, Richa , Thottempudi, Neeharika , D'Souza, Marissa, Aziz, Yasmin , Yaghi, Shadi , Goldstein, Eric , Chen, Lucia , Stamm, Brian , Siegler, James E.

Mayo Clinic

Journal of the American Heart Association | September 25, 2025 | Volume: 14 | Issue: 19 | Pages: No page available

10.1161/jaha.125.041500 | PMID 40996035 Get It

Background Intracranial occlusions in embolic stroke of undetermined source are histopathologically similar to cardiac sources of embolism. Whether patients with embolic stroke of undetermined source and intracranial occlusion benefit from anticoagulation is unknown. Methods A multicenter retrospective cohort of adults with cryptogenic stroke was queried for patients with proximal or medium/distal vessel occlusion. The primary outcome was recurrent ischemic stroke, which was assessed in unadjusted and adjusted Cox proportional hazards models and repeated following 1:1 propensity score matching and biweight kernel density matching. Results Of the 2328 patients who were followed over a median of 1.31 years (interquartile range, 0.34–2.85), 999 (42.6%) had an intracranial occlusion. When compared with patients without an intracranial occlusion, those with an occlusion had fewer atherosclerotic vascular risk factors, more severe symptoms, and less severe cerebral microvascular disease. The rate of recurrent stroke was similar between patients with versus without an intracranial occlusion (6.8%/year [95% CI, 5.7–8.2] versus 7.0%/year [95% CI 6.0–8.1]; adjusted hazard ratio [HR], 1.09 [95% CI, 0.77–1.55]). There was no association between occlusion and recurrent stroke in the adjusted propensity score matching (HR, 1.01 [95% CI, 0.64–1.59]) or kernel density models (HR, 0.95 [95% CI, 0.62–1.45]). There was no interaction between occlusion and treatment with anticoagulation, sex, age, or high‐risk sources of embolism for the primary outcome in the unmatched and matched analyses. Conclusions Intracranial occlusion in patients with embolic stroke of undetermined source is not associated with a greater risk of recurrence when compared with patients without an intracranial occlusion. There was no difference in rate of recurrent stroke with anticoagulation when stratified by presence or absence of occlusion.